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Abstract 
PURPOSE: The objectives were to determine the effects of caffeine ingestion 
and mouth rinsing on cycling performance, and to assess whether the CYP1A2 gene 
is related to the size of the performance effects. METHODS: Thirty-eight recreational 
cyclists completed four simulated 3-kilometer time trials (TT). Subjects ingested 
either 6mg/kgBW of caffeine or placebo one hour prior to each TT. Additionally, 25 
ml of 1.14% caffeine, or placebo solution was mouth rinsed before each TT. 
Treatments were: placebo ingestion+placebo rinse (Placebo), placebo 
ingestion+caffeine rinse (Rinse), caffeine ingestion+caffeine rinse (Ingestion+Rinse), 
caffeine ingestion+placebo rinse (Ingestion). Subjects were genotyped and classified 
as AA homozygotes or C allele carriers for the rs762551 polymorphism in CYP1A2. 
Magnitude based inferences were used to evaluate treatment differences. RESULTS: 
Both Ingestion+Rinse (‘likely’) and Ingestion (‘possibly’) improved performance 
compared to Placebo. Performance differences between Ingestion+Rinse and 
Ingestion and between Rinse and Placebo were ‘likely trivial.’ C allele carriers 
experienced greater gains (‘likely’) with Ingestion compared to AA homozygotes. 
Additional analyses revealed that caffeine intake conferred larger benefits for 
subjects that performed trials prior to 10am. CONCLUSIONS: Caffeine ingestion, but 
not mouth rinse, improved cycling performance. C allele carriers experienced the 
largest improvement in performance with caffeine ingestion, especially prior to 
10am. 
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Chapter One 
Introduction 
Consumption of caffeinated beverages began no later than 750-1000AD (19). 
Caffeine was first isolated by Friedrich Ferdinand Runge in 1819 with the intention 
of treating diseases associated with aging (39). Today, caffeine is the most 
consumed psychoactive drug in the world, with an estimated worldwide daily intake 
of ~75mg/person (18).  Fredholm et al. reported that Scandinavian countries 
consume >400mg caffeine/person/day, whereas countries such Nigeria and Angola 
consume as little as 5mg caffeine/person/day (18). The widespread use of caffeine 
in humans is primarily attributed to the stimulatory effect of caffeine on the central 
nervous system, enhancing alertness. Caffeine has also proliferated into the world of 
athletics and the last four decades have yielded sufficient scientific evidence for the 
efficacy of caffeine ingestion on sprinting and endurance exercise performance (14). 
In cyclists, caffeine can enhance 1km and 4km sprinting performance (42, 49). 
Likewise, caffeine provision can improve short duration swimming performance (8), 
rowing (5), running (20), and performance in variable intensity activities such as 
tennis and team sports (29, 43). In 2004, a meta-analysis of 40 studies revealed that 
caffeine intake markedly influences endurance performance, confirming the 
effectiveness of caffeine use in events greater than 60 minutes (14). 
The mechanism by which caffeine improves performance has drawn 
considerable interest. Early thinking was that caffeine spared muscle glycogen and 
enhanced fat oxidation during endurance exercise (11, 15, 27, 45) but this notion 
has largely been discarded (21, 22, 23, 31). Caffeine is now believed to deliver its 
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effects through the central nervous system (17). Adenosine decreases neuron firing 
and the release of most neurotransmitters including acetylcholine, dopamine, and 
noradrenaline (44). Caffeine is an adenosine antagonist that competitively binds to 
adenosine receptors, thereby promoting continued neuron activity. Likely through 
this mechanism, caffeine provision can suppress ratings of perceived exertion and 
pain (11, 37), and increase neural excitability (47) thereby enhancing athletic 
performance. 
Though it is evident that caffeine ingestion can improve performance in 
events of short and long durations, not all subjects experience the same benefits. 
There is considerable individual variability with respect to caffeine responsiveness, 
with some subjects exhibiting no effect at all (6). Genetics have consequently been 
implicated as an explanation for the individualized ergogenic response to caffeine 
ingestion (9). In an attempt to address whether or not genetics contribute to the 
individual ergogenic effect of caffeine, our laboratory recently determined that 
individuals homozygous for a single nucleotide (A) polymorphism at intron 1 of the 
cytochrome P450 (CYP1A2) gene appeared to experience a larger ergogenic effect 
following caffeine ingestion (50). Therefore, there may be a genetic predisposition 
for responsiveness to caffeine ingestion that is greater in some people than in 
others. Caffeine is metabolized in the liver by the cytochrome P450-1A2 enzyme, 
which is coded for by the CYP1A2 gene (51). Being homozygous for the A allele 
increases the inducibility of the P450-1A2 enzyme (41). If the expression of the 
P450-1A2 enzyme is increased, as it is in individuals with the A/A genotype, then 
the rate of caffeine metabolism may also increase. Quicker metabolism of caffeine in 
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the liver may lead to a higher concentration of caffeine metabolites in the blood that 
in turn would act on the central nervous system, consequently improving 
performance.  
 Beaven and colleagues recently reported that without ingesting, but by 
rinsing caffeine in the mouth, repeated sprinting performance is enhanced in 
cyclists (1). It is logical to speculate that there are unidentified caffeine receptors in 
the oral cavity that respond to the presence of caffeine by transmitting signals to the 
areas of the brain involved in reward and motor activity, much like what has been 
shown with carbohydrates (6). Interestingly, in the same study by Beaven, it was 
also revealed that a caffeine-carbohydrate mouth rinse improved performance 
beyond that of only a carbohydrate mouth rinse, providing more support for an oral 
receptor in the mouth for caffeine (1). More research is necessary to profile the 
efficacy of a caffeine mouth rinse on performance, particularly in real-world time 
trial scenarios. The idea that mouth rinsing with caffeine can enhance performance 
through a mechanism not influenced by liver caffeine metabolism invites the 
possibility that genetic non-responders to caffeine ingestion may be able to derive 
performance benefits from a caffeine mouth rinse. Additionally, because of the 
presumed mechanisms through which caffeine consumption and mouth rinsing 
elicits performance gains, one might expect there to be a further improvement in 
performance when mouth rinsing in combination to ingesting caffeine than when 
only ingesting caffeine. 
In contrast to Beaven’s work, others have shown that a caffeine mouth rinse 
given throughout a 60 minute cycling time trial does not seem to improve 
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performance (12), bringing into question the efficacy of a caffeine mouth rinse for 
sustained power output. Worth noting is that in a subgroup of subjects that did not 
report regular caffeine consumption there was an observed ergogenic effect to the 
caffeine mouth rinse even though the mouth rinse in this study contained a 
relatively low concentration of caffeine that has not been shown to improve 
performance during caffeine ingestion (28). Some studies have demonstrated that 
“non-caffeine users” (<50mg caffeine/day) experience a heightened performance 
benefit during caffeine ingestion (2) and that performance gains are attenuated in 
habitual caffeine users (16). 
This project was designed to address the questions outlined above. 
Specifically, we aim to determine the effectiveness of a caffeinated mouth rinse on 
sustained performance. As previously stated the presumed mechanisms of action of 
caffeine mouth rinsing and ingestion are on the oral receptors and brain, 
respectively. Differing enhancement in performance between genetic 
polymorphisms, or between habituation levels of subjects will allow for the 
assumption that the physiological effect of these factors occurs at either the liver or 
CNS. In those that do not respond to caffeine ingestion it is possible that a caffeine 
mouth rinse will elicit a performance enhancing effect that was otherwise not 
observed by caffeine ingestion. If there is a separate mechanism of caffeine mouth 
rinsing on the CNS then those who do not respond to caffeine ingestion potentially 
could experience a performance enhancing effect of a caffeine mouth rinse. 
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Aims and Hypotheses 
Aim 1: To determine if a pre-exercise caffeine mouth rinse improves 3km cycling
 performance compared to placebo. 
Hypothesis 1: A pre-exercise caffeine mouth rinse will improve 3km cycling
 performance compared to a placebo. 
 
Aim 2: To determine if a caffeine mouth rinse influences 3km cycling performance in 
 C allele carriers of the CYP1A2 polymorphism. 
Hypothesis 2: Genetic non-responders (C allele carriers) will not exhibit as great of a
 performance improvement in response to a pre-exercise caffeine mouth
 rinse when compared to placebo as genetic responders (A/A homozygous)
 individuals. 
 
Aim 3: To determine if a pre-exercise caffeine mouth rinse improves 3km cycling
 performance among “caffeine-users” to a greater degree than “caffeine non
 -users.” 
Hypothesis 3: “Caffeine non-users” will exhibit a greater performance benefit in
 response to a pre-exercise caffeine mouth rinse than “caffeine-users.” 
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Aim 4: To determine if a pre-exercise caffeine mouth rinse in addition to caffeine
 ingestion improves 3km cycling performance compared to caffeine ingestion
 alone. 
Aim 4: A pre-exercise caffeine mouth rinse in addition to caffeine ingestion will
 improve 3km cycling performance more than caffeine ingestion alone. 
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Significance 
 The current study will be the first to examine the performance enhancing 
effect of a caffeinated mouth rinse on prolonged cycling, providing further evidence 
of the actions of caffeine in the oral cavity. The effectiveness of caffeine ingestion in 
combination with a caffeine mouth rinse at enhancing performance will be 
examined to determine the potential additive effects of these two methods of 
caffeine administration. Additionally, this study will yield further insight to the 
factors that can effect performance improvement in regards to caffeine ingestion 
including genetic responsiveness and previous caffeine intake habits. These results 
may influence the use of caffeine in athletes competing in events of similar duration. 
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Chapter Two 
Methods 
Subjects 
 All subjects will be recruited from James Madison University and will be 
required to have performed, at minimum, “occasional” cycling in their weekly 
exercise routine. Approximately 40 recreationally trained male and female subjects 
will provide written informed consent to participate in the study approved by the 
James Madison University Institutional Review Board.  
 
Testing Procedures 
Cardiovascular Fitness Test - VO2max 
 Following height and body weight measurements, subjects will perform an 
incremental exercise test on a Velotron cycle ergometer (Seattle, WA, USA) until 
volitional exhaustion.  Subjects will begin with a 5-minute warm-up at a self-
selected pace. The subjects will then be prompted to select an intensity that “they 
can maintain for 60-minutes” to begin the test. The workload will then be increased 
every minute in 15 Watt (W) increments until the subject reaches volitional fatigue. 
Breath samples will be collected throughout the test and oxygen consumption 
(VO2max) will be measured via Moxus Modular Metabolic System (AEI Technologies, 
Bastrop, TX, USA). Heart rate will be measured via Polar heart rate monitor (Lake 
Success, New York, USA). A fan set on the “medium” setting will be placed 2 meters 
in front of the Velotron for cooling purposes. All subjects will receive strong verbal 
encouragement throughout the cardiovascular fitness test. 
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Familiarization and Experimental Trials 
 Each subject will perform six exercise trials on a Velotron cycle ergometer, 
with 3-7 days between each trial. The first two trials will serve as familiarization 
trials with the subsequent four trials serving as experimental trials in a double 
blind, randomized, counter-balanced, placebo controlled fashion. The subjects will 
then be asked to perform a 5-minute warm-up at a self-selected intensity. Two 
mouth rinses will be provided during the warm-up; one given immediately at the 
onset of the warm-up, and one 30 seconds before completion of the warm-up. 
Subjects will be instructed to swish the mouth rinse for 5 seconds, during which the 
researcher will count down from 5. Following the warm-up subjects will perform a 
3km time trial. Subjects will be instructed to treat each trial as if they are in a race. 
Subjects will not receive verbal feedback or encouragement from the investigators 
and no visual feedback from the time trial will be provided with the exception of 
elapsed distance. 
 
Supplementation Protocol 
 No supplementation will be given during the familiarization trials other than 
two practice mouth rinses (water only). During the experimental trials subjects will 
be given a 25ml mouth rinse solution at room temperature containing either: A) 
300mg caffeine, 1g saccharine, and 25ml of water (rinse containing 1.14% caffeine) 
or B) a flavor-matched placebo containing 6g saccharine, and 25ml of water. 
Additionally, a 6mg/kg of body weight capsule containing either anhydrous caffeine 
or all-purpose flour (placebo) will be ingested 1 hour prior to each treatment trial. 
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The following are the four treatment conditions that will be administered: 1) 
placebo capsule + placebo mouth rinse. 2) placebo capsule + caffeine mouth rinse 3) 
caffeine capsule + caffeine mouth rinse. 4) caffeine capsule + placebo mouth rinse. 
 
Dietary and Exercise Control 
Diet 
 Subjects will be provided with instructions for recording food intake so that 
subsequent dietary intake can be replicated. All subjects will record food intake for 
24 hours prior to all experimental trials and will be asked to repeat food intake for 
each treatment trial so that caloric intake is identical between trials. Subjects will be 
given a copy of their previous food log so that they can easily repeat their diet for 
the subsequent trial. Subjects will abstain from any alcohol, caffeine, and food, for 
24, 12, and 2 hours prior to each experimental trial respectively. Dietary records 
will be obtained prior to each experimental trial. 
 
Exercise 
 All subjects will record daily physical activity for 48 hours prior to 
experimental trials and will be asked to repeat daily physical activity for each 
experimental trial. Subjects will be given a copy of their previous exercise log so that 
they can easily repeat their physical activity for the subsequent trial. Subjects will be 
asked to abstain from any heavy exercise 48 hours prior to each experimental trial. 
Exercise records will be obtained prior to each experimental trial. 
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DNA Sampling 
Blood Sampling 
 Approximately 3 ml of blood will be obtained from an antecubital vein after 
the final time trial. Blood will then be stored in a -80 degree F freezer until DNA 
extraction takes place. DNA will be extracted via Illustria Blood GenomicPrep mini 
spin kit (GE Healthcare, Buckinghamshire, UK). Genotyping will then be performed 
using restriction fragment length polymorphism-polymerase chain reaction (RFLP-
PCR). Following blood genotyping, subjects will be grouped as A/A homozygous and 
C allele carriers. 
 
Treatment Blinding Efficacy 
 Upon conclusion of the study, subjects will be asked to identify which 
treatment they received for each of the four treatment trials to confirm effectiveness 
of the treatment blinding procedures. 
 
Statistical Analysis 
Univariate Analysis of Variance (ANOVA) will be applied to determine 
treatment differences for all variables. Simple contrasts between treatment 
conditions will be used to generate P values for subsequent analysis as described 
below. Statistical analyses will be performed using IBM Statistical Package for Social 
Sciences (SPSS) 21 for Macintosh (SPSS Inc., Chicago, IL, USA).   
Magnitude-based inferences about the data will be derived using methods 
described by Hopkins and colleagues (Hopkins et al., 2009). A previously 
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established ‘smallest worthwhile change’ in performance will be used as the 
threshold value for a substantial treatment effect (separate treatment conditions vs. 
placebo) (Hopkins, 2004). The smallest worthwhile change in performance will be 
defined as 0.3 x the within subject variability across repeated time trials (Hopkins, 
2004). The coefficients of variability for the performance parameters will be derived 
from the familiarization trials of the current investigation. 
A published spreadsheet (Hopkins, 2007) will then be used to determine the 
likelihoods of the true treatment effect (of the population) reaching the substantial 
change threshold (0.3 x CV); these will be classified as <1% almost certainly no 
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely, 
95-99% = very likely, and >99% = almost certain. If the percent chance of the effect 
reaching the substantial change threshold is <25% and the effect is clear, it will be 
classified as a ‘trivial’ effect. If 90% confidence intervals included values that 
exceeded the substantial change threshold for both a positive and negative effect, 
effects will be classified as unclear (>5% chance of reaching the substantial 
threshold for both a positive and negative effect). For ease of interpretation data 
will be displayed as raw means ± SD. 
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Chapter Three 
Manuscript 
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Abstract 
PURPOSE: The objectives were to determine the effects of caffeine ingestion 
and mouth rinsing on cycling performance, and to assess whether the CYP1A2 gene 
is related to the size of the performance effects. METHODS: Thirty-eight recreational 
cyclists completed four simulated 3-kilometer time trials (TT). Subjects ingested 
either 6mg/kgBW of caffeine or placebo one hour prior to each TT. Additionally, 25 
ml of 1.14% caffeine, or placebo solution was mouth rinsed before each TT. 
Treatments were: placebo ingestion+placebo rinse (Placebo), placebo 
ingestion+caffeine rinse (Rinse), caffeine ingestion+caffeine rinse (Ingestion+Rinse), 
caffeine ingestion+placebo rinse (Ingestion). Subjects were genotyped and classified 
as AA homozygotes or C allele carriers for the rs762551 polymorphism in CYP1A2. 
Magnitude based inferences were used to evaluate treatment differences. RESULTS: 
Both Ingestion+Rinse (‘likely’) and Ingestion (‘possibly’) improved performance 
compared to Placebo. Performance differences between Ingestion+Rinse and 
Ingestion and between Rinse and Placebo were ‘likely trivial.’ C allele carriers 
experienced greater gains (‘likely’) with Ingestion compared to AA homozygotes. 
Additional analyses revealed that caffeine intake conferred larger benefits for 
subjects that performed trials prior to 10am. CONCLUSIONS: Caffeine ingestion, but 
not mouth rinse, improved cycling performance. C allele carriers experienced the 
largest improvement in performance with caffeine ingestion, especially prior to 
10am. 
 
Keywords: CYP1A2, genetics, circadian rhythm, mouthwash 
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Introduction 
Caffeine intake can improve high intensity performance across a continuum 
of activities, including swimming (Collomp et al., 1992), rowing (Bruce et al., 2000), 
running (Wiles et al., 1992; Glaister et al., 2008), cycling (Wiles et al., 2006; Santos et 
al., 2013), and variable intensity activities (Schneiker et al., 2006; Klein et al., 2012). 
Though unsettled, caffeine is believed to deliver its performance enhancing effects 
through the central nervous system by blocking adenosine receptors (Ribeiro & 
Sebastião, 2010) and increasing neural excitability (Walton et al., 2003). This can 
enhance motor output (Black et al., 2014) and suppress ratings of perceived 
exertion and pain (Doherty et al., 2005; Motl et al., 2003). 
Considerable individual variability associated with the performance benefits 
of caffeine has long been recognized (Doherty et al., 2002; Meyers & Cafarelli, 2005; 
Robertson et al., 1978). Genetics have been offered as a possible explanation and 
viable gene candidates have been identified. For instance, there are genetic 
variations of the primary enzyme responsible for caffeine metabolism – CYP1A2 
(Yang et al., 2010). Homozygosity for the A allele at intron 1 of the CYP1A2 gene 
increases the inducibility of the enzyme (Sachse et al., 2009). This presumably 
influences the rate of caffeine metabolism and resultant concentrations of caffeine 
and caffeine metabolites in the blood. Based on this concept our laboratory recently 
investigated whether CYP1A2 genotype impacts the performance benefits of 
caffeine. We reported that individuals homozygous for the A allele experienced a 
larger ergogenic effect (Womack et al., 2012). This may partially explain the variable 
performance benefits of caffeine intake. 
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 Interestingly, some investigators have recently observed that rinsing caffeine 
in the mouth, without ingestion, enhances repeated sprint (Beaven et al., 2013) and 
30-minute (Bottoms et al., 2014) cycling performance. It is possible that 
unidentified receptors in the oral cavity provide afferent feedback in a manner that 
enhances physical performance, much like what has been shown with carbohydrate 
rinsing (Chambers et al., 2009). However, recent data refuting the benefits of a 
caffeine rinse for 60-min cycling performance (Doering et al., 2013) calls this into 
question and necessitates more work in this area. If mouth rinsing with caffeine 
ultimately proves beneficial, it could be a practical strategy to avoid the genetic 
disadvantages associated with alterations in caffeine metabolism, as the ergogenic 
effect of mouth rinsing would not be affected by hepatic clearance. 
Therefore, this study was designed to assess the efficacy of caffeine mouth 
rinsing on 3-km cycling time trial performance and to determine if caffeine mouth 
rinsing affects the magnitude of performance gains influenced by the CYP1A2 
polymorphism. Because subjects self-selected the time of day at which they 
performed their laboratory trials, we also had the opportunity to preliminarily 
examine the possibility that time of day alters the effects of caffeine on cycling 
performance 
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Materials and Methods 
Subjects 
 Thirty-eight recreationally trained male and female subjects from James 
Madison University participated in this study (demographics reported in Table 2). 
Subjects were required to have performed, at minimum, “occasional” cycling (one 
day per week) in their typical weekly exercise routine.  Subjects were informed of 
the experimental procedures and risks prior to giving written consent. The study 
was approved by the James Madison University Institutional Review Board.  
 
Cardiorespiratory Fitness 
 Following height and body weight measurements, subjects performed an 
incremental exercise test to exhaustion on a bicycle ergometer (Velotron, 
Racermate, Inc., Seattle, WA, USA) to determine VO2max. Subjects began with a 5-
minute warm-up at a self-selected intensity. Subjects then were prompted to select 
an intensity that could be maintained for 60-minutes to begin the test. Workload 
was increased in 15 W increments every minute until volitional fatigue. Metabolic 
measurements were assessed via Moxus Modular Metabolic System (AEI 
Technologies, Pittsburgh, PA, USA) throughout the test and VO2max was determined 
by the highest 30 s mean oxygen uptake value. A fan set on the medium setting was 
placed 2 meters in front of the ergometer to cool subjects. 
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Supplementation 
 A randomly counterbalanced, double blind, placebo controlled design was 
implemented to compare the effects of the four treatment conditions. During the 
experimental trials subjects were given two 25ml mouth rinse solutions at room 
temperature containing either: A) 300mg caffeine (NutraBio Labs, Inc., Middlesex, 
NJ), 1g saccharine (Sweet’N Low, Brooklyn, NY), and 25ml of water (rinse containing 
1.14% caffeine) or B) a flavor-matched placebo containing 6g saccharine, and 25ml 
of water. Additionally, a 6mg/kg body weight capsule containing either anhydrous 
caffeine or all-purpose flour (placebo) was ingested 1 hour prior to each treatment 
trial. The four treatments consisted of a 2 x 2 factorial of capsule and mouth rinse 
treatments: 1. placebo capsule + placebo mouth rinse (Placebo) 2. placebo capsule + 
caffeine mouth rinse (Rinse) 3. caffeine capsule + caffeine mouth rinse 
(Ingestion+Rinse) 4. caffeine capsule + placebo mouth rinse (Ingestion). 
 
Performance Trials 
 Each subject performed six exercise trials (two familiarization trials followed 
by four experimental trials) on the aforementioned cycle ergometer, with 3-7 days 
between each trial. Trials were performed at the same time of day to eliminate any 
possible within-subject circadian effects on performance. The subjects performed a 
5-minute warm-up at a self-selected intensity. Two mouth rinses were provided 
during the warm-up; one immediately at the onset of the warm-up, and another 30 
seconds before completion of the warm-up. Subjects swirled the mouth rinse for five 
seconds and then expectorated the rinse. Following the warm-up subjects 
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performed a 3km time trial. Familiarization trials were identical to the experimental 
trials, with the exception that subjects rinsed with water. Subjects were instructed 
to treat each trial as a competition. Subjects did not receive verbal feedback or 
encouragement from the investigators and no visual feedback from the time trial 
were provided, with the exception of elapsed distance. 
 Average power output during the first, second, and third kilometers were 
also analyzed to determine if any pacing differences were present between 
treatments. 
 
Time of Day 
 Subjects were divided into two separate groups based on the time of day that 
they performed laboratory trials. 10:00am was selected as the threshold as it 
emerged as a natural breakpoint and created a group of 15 subjects that performed 
Early trials and 23 subjects that performed Late trials. To evaluate the effect of 
caffeine ingestion on change in performance the Ingestion and Ingestion+Rinse 
treatments were averaged for each subject and then compared to placebo. 
 
Dietary and Exercise Control 
 Subjects recorded food intake for 24 hours prior to the initial experimental 
trial and were instructed to replicate food intake for the 24-hour period prior to 
each experimental trial. Subjects were instructed to abstain from any alcohol (24 
hrs), caffeine (12 hrs), and food intake (2 hrs) prior to each experimental trial. All 
subjects recorded daily physical activity for 48 hours prior to experimental trials. 
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Subjects were instructed to maintain consistent exercise habits between trials and 
to abstain from any heavy and/or unaccustomed exercise 48 hours prior to each 
experimental trial. 
 
DNA Sampling 
 Blood samples [~3ml sample – 5ml BD Vacutainer tube (Becton Dickinson & 
Company, Franklin Lakes, NJ, USA)] were obtained from an antecubital vein after the 
final time trial. Blood was then stored at -80 oC until DNA extraction. DNA was 
extracted via Illustria Blood GenomicPrep mini spin kit (GE Healthcare, 
Buckinghamshire, UK). Genotyping was then performed using restriction fragment 
length polymorphism-polymerase chain reaction (RFLP-PCR). Following 
genotyping, subjects were grouped as AA homozygous (i.e. ‘fast’ metabolizers) and C 
allele carriers (i.e. ‘slow’ metabolizers) of the rs762551 single nucleotide 
polymorphism in the CYP1A2 gene. 
 
Statistical Analysis 
Univariate Analysis of Variance (ANOVA) was applied to determine 
treatment differences. Simple contrasts between treatment conditions were used to 
generate P values for analyses described below. Independent t-tests were used for 
between group comparisons of genotype, and time of day. All data were log 
transformed to diminish the effects of nonuniformity. Statistical analyses were 
performed using IBM Statistical Package for Social Sciences (SPSS) 21 for Macintosh 
(SPSS Inc., Chicago, IL, USA).   
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Magnitude-based inferences about the data were derived using methods 
described by Hopkins and colleagues (Hopkins et al., 2009). A previously 
established ‘smallest worthwhile change’ in performance was used as the threshold 
value for a substantial treatment effect (separate treatment conditions vs. placebo) 
(Hopkins, 2004). The smallest worthwhile change in performance was defined as 
0.3 x the within subject variability (CV=2.3%; calculated from familiarization trials) 
across repeated time trials, which translated to a 2.1 s difference in performance 
(Hopkins, 2004).  
A published spreadsheet (Hopkins, 2007) was then used to determine the 
likelihood of the true treatment effect (of the population) reaching the substantial 
change threshold (0.3 x CV); these were classified as <1% almost certainly no 
chance, 1-5% = very unlikely, 5-25% = unlikely, 25-75% = possible, 75-95% = likely, 
95-99% = very likely, and >99% = almost certain. If the percent chance of the effect 
reaching the substantial change threshold was <25% and the effect was clear, it was 
classified as a ‘trivial’ effect. If 90% confidence intervals included values that 
exceeded the substantial change threshold for both a positive and negative effect, 
effects were classified as unclear (>5% chance of reaching the substantial threshold 
for both a positive and negative effect). For ease of interpretation data is displayed 
as raw means ± SD. 
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Results 
Performance 
Ingestion+Rinse ‘likely’ improved performance by 1.4% ± 3.3% when 
compared with Placebo, whereas Ingestion ‘possibly’ enhanced performance by 
1.1% ± 4.1%. Rinse had a ‘likely trivial’ effect on time trial performance. 
Performance differences between Ingestion+Rinse and Ingestion and between Rinse 
and Placebo were ‘likely trivial’. Mean performance times are displayed in Table 1 
and mean difference of treatment effects (treatment times – placebo times) with 90 
percent confidence intervals are displayed in Figure 1. 
 
Genetics 
Twenty-one (55%) subjects were homozygous for the A allele and seventeen 
(45%) were C allele carriers. Descriptive characteristics of the two genotype groups 
are shown in Table 2. Among C allele carriers, performance was ‘likely’ improved by 
2.0% ± 4.0% and by 1.8% ± 3.4% with both Ingestion and Ingestion+Rinse 
respectively, whereas AA homozygotes ‘possibly’ benefited by 1.0% ± 3.2% with 
Ingestion+Rinse. All other treatment effects were ‘unclear’. Note that there ‘likely’ 
was a difference in performance improvement with Ingestion between the AA and 
AC genotypes. Mean treatment effects are displayed in Figure 2. 
 
Time of Day 
Fifteen (39%) subjects performed trials prior to 10am (Early), of whom 
seven were C allele carriers and eight were AA homozygotes. Twenty-three (61%) 
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subjects performed trials later than 10am (Late), of whom ten were C allele carriers 
and thirteen were AA homozygotes. Performance was ‘almost certainly’ improved 
with caffeine ingestion in Early subjects by 2.0 ± 2.5%, and ‘possibly’ improved in 
Late subjects by 0.7 ± 4.3%. Among C allele carriers, caffeine ingestion ‘almost 
certainly’ and ‘possibly’ improved performance by 3.5 ± 2.1% and 0.6 ± 2.1% in 
Early and Late subjects respectively. Mean treatment effects are displayed in Figure 
3. 
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Discussion 
The primary goal of this project was to determine if caffeine mouth rinsing 
and ingestion, alone and in combination, benefit 3km cycling performance, and if 
effects occurred regardless of CYP1A2 genotype. Although caffeine ingestion 
improved performance compared to placebo, mouth rinsing had only a trivial effect, 
regardless of genotype. Also, in contrast to a recent investigation from our 
laboratory (Womack et al., 2014), C allele carriers experienced greater performance 
gains with caffeine ingestion than AA homozygotes. More data need to be gathered 
to provide a sound explanation for this observation. Finally, the post-hoc time of day 
analyses revealed that caffeine imparted marked benefits when trials were 
performed Early compared to Late. To our knowledge, this is the first evidence that 
time of day may impact the magnitude of the effect that caffeine has on cycling 
performance. 
The current data conflict with previous reports that caffeine mouth rinsing 
can augment 30-minute cycling performance (Bottoms et al., 2014) and power 
output during repeated sprints (Beaven at al., 2013). However, in line with the 
current results, Doering’s work indicates that caffeine rinsing does not affect ~60-
min cycling performance (Doering et al., 2013). We were not able to identify 
experimental commonalities or differences that would explain why these protocols 
yielded different results. So, when our data are combined with Doering, and 
considered with the fact that there are no known oropharangeal receptors for 
caffeine, we question the utility of caffeine rinsing for performance. However, there 
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is enough support (Bottoms et al., 2014; Beaven et al. 2013) to warrant follow-up 
work before unequivocal conclusions are made. 
Despite the failure of a caffeine mouth rinse to improve TT performance, 
caffeine ingestion did enhance performance, as has been demonstrated previously 
during cycling performances of similar duration (Wiles et al., 2006; Santos et al., 
2013). The observation that caffeine intake improved performance supports the 
efficacy of the current study design and strengthens the interpretation of the mouth 
rinse findings. In light of the overall mouth rinse results, caffeine mouth rinsing did 
not benefit the genetic ‘non-responders’, nor did it further benefit performance 
when provided along with caffeine ingestion. 
We recently reported that AA homozygotes exhibited larger performance 
benefits with caffeine ingestion, compared to their C allele counterparts (Womack et 
al. 2014). Thus we expected that the AA homozygotes again would experience a 
more marked performance enhancement. Surprisingly, the C allele carriers 
experienced greater gains in performance with caffeine ingestion than did the AA 
homozygotes. Because of the size and individual consistency of the effect across 
projects, we do not believe that either finding is coincidental. Yet, there is no clear 
explanation for the opposing results. One difference between studies is training 
status. The previous sample population consisted of competitive cyclists, whereas 
subjects in the current study were recreational cyclists who reported cycling only 
~2 days per week. CYP1A2 expression is induced following acute exercise 
(Kochanska-Dziurowicz et al., 2014) and exercise training (Vistisen et al., 1992). 
Additionally, some have shown that adenosine receptor (the target of caffeine and 
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caffeine metabolites) density in skeletal and cardiac muscle is greater in endurance-
trained than untrained men (Mizuno et al. 2005). Therefore, it may be that training 
history and/or current fitness level influences the substrate-receptor interaction 
between caffeine/metabolites and adenosine receptors, thereby altering the 
genotype x caffeine effect. Prospective studies should consider evaluating 
differences in caffeine metabolites across genotype and training status. 
Though not a priori, the time of day analysis revealed that the benefits of 
caffeine may be exaggerated Early (<10:00am) in the day. Caffeine ingestion 
improved performance to a greater extent in the Early trials compared to the Late 
trials. This is in line with recent findings that caffeine ingestion has a larger effect on 
neuromuscular performance in the morning than in the afternoon. It seems that the 
improvement in performance seen in the morning simply elevates performance to 
what is seen in the afternoon during placebo conditions, with only minimal 
improvement due to caffeine ingestion in the afternoon (Mora-Rodriguez et al., 
2012; Mora-Rodriguez et al., 2014). Additionally, we found that the C allele carriers 
seemed to be driving the effect in the Early trials. All seven C allele carriers who 
performed Early trials performed better with caffeine ingestion, whereas this was 
true in only five of the eight Early AA carriers. Interestingly, CYP1A2 activity is 
elevated in the morning compared to the evening (Perera et al., 2013), which may 
contribute to the ergogenic effect of caffeine; consequently adding yet another 
variable to consider when interpreting the physiological effects of caffeine intake.  
It is important to note that all but one of the Early subjects were fasted (over 
night) whereas twenty of the twenty-three Late subjects had eaten during the days 
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of their performance trials, raising the possibility that feeding status factored into 
the time of day results. However, improvements in performance due to caffeine 
ingestion have been demonstrated following 6-12 hour fasting (MacIntosh & Wright, 
1995; Bruce et al., 2000), and when feedings have taken place approximately 2 
hours before testing (Collomp et al., 1992; Schneiker et al., 2006). Moreover, the 
previously mentioned time-of-day study by Mora-Rodriguez et al. gave subjects a 
624kcal bolus one hour prior to all testing, suggesting that fasting does not play a 
role in the ergogenic effect of caffeine (2014). To our knowledge no studies have 
directly examined the effect of feeding status on performance following caffeine 
ingestion. Future investigations should determine whether the time of day and/or 
fasting influence the performance response to caffeine ingestion. 
The present study demonstrates that caffeine mouth rinsing does not affect 
3km cycling performance in recreational cyclists. As expected there was an 
improvement in 3km performance with caffeine ingestion, but there was no further 
improvement with caffeine ingestion and mouth rinse in combination. Surprisingly, 
there was a greater performance enhancement in C allele carriers compared to AA 
homozygotes following caffeine ingestion, thus necessitating follow-up work to 
explain the dissimilar results compared to our previous work. Finally a greater 
performance enhancement with caffeine ingestion was observed in Early trials 
compared to Late trials. 
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Perspectives 
 The present study provides additional evidence of genetic (genotype) and 
circadian (time of day) factors that affect the ergogenic value of caffeine intake and 
may allow for prescription of more personalized caffeine intake strategies to 
maximize performance.  For example, perhaps genetics contribute to caffeine 
metabolism in a manner that would affect the optimal timing and dosage for a 
particular subject. Further, the time at which caffeine is consumed may strongly 
influence the magnitude of the desired effect. Future research is critical for the 
development of personalized caffeine intake guidelines for athletes. 
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Figure Legends 
Figure 1 
Effects of Caffeine Mouth Rinsing and Ingestion on 3km Time Trial Performance: 
Circles indicate mean treatment differences from placebo and bars depict a ± 90% 
confidence interval of Rinse, Ingestion, and Ingestion+Rinse vs. Placebo. Dashed lines 
signify threshold value for a meaningful effect (0.3 x CV). * Signifies a ‘likely’ 
improvement in performance. † Signifies a ‘possible’ improvement in performance. 
Placebo = placebo ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse, 
Ingestion+Rinse = caffeine ingestion+caffeine rinse, Ingestion = caffeine 
ingestion+placebo rinse. 
 
Figure 2 
Effect of Genotype on the Treatment Effect of Caffeine Mouth Rinse and Ingestion 
During 3km Time Trial Performance: Bars indicate mean treatment differences from 
placebo and bars depict a ± 90% confidence interval of Rinse, Ingestion, and 
Ingestion+Rinse vs. Placebo. * Signifies a ‘likely’ improvement in performance. † 
Signifies a ‘possible’ improvement in performance. ‡ Signifies a ‘likely’ difference in 
performance improvement between the AA and AC Genotypes. Placebo = placebo 
ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse, Ingestion+Rinse = 
caffeine ingestion+caffeine rinse, Ingestion = caffeine ingestion+placebo rinse. 
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Figure 3 
Influence of Time of Day on the Treatment Effect of Caffeine Ingestion During 3km 
Time Trial Performance: Bars depict the treatment effects (± 90% CI) of Overall, C 
allele carrier, and AA homozygote performance with caffeine ingestion. * Signifies an 
‘almost certain’ improvement in performance. † Signifies a ‘possible’ improvement 
in performance.
 
       33 
 
 
† Signifies a ‘possible’ improvement in performance compared to Placebo. * Signifies a ‘likely’ improvement in performance 
compared to Placebo. Placebo = placebo ingestion+placebo rinse, Rinse = placebo ingestion+caffeine rinse, Ingestion+Rinse = 
caffeine ingestion+caffeine rinse, Ingestion = caffeine ingestion+placebo rinse. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 3-km Time Trial Performance
Placebo Rinse Ingestion Ing+Rinse
Mean Time ± SD (seconds) 313.7 ± 30.9 314.1 ± 29.1 310.2 ± 30.9† 309.0 ± 27.4*
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Table 2. Descriptive data of subjects for AA homozygotes and C allele carriers
All Subjects (n = 38) AA (n = 21) C (n = 17)
Height (cm) 171.0 ± 13.7 167.2 ± 16.9 175.7 ± 6.2
Weight (kg) 70.9 ± 11.9 68.0 ± 13.8 74.5 ± 8.0
Age (years)  21.6 ± 1.5 20.8 ± 1.4 21.6 ± 1.5
VO2 max (ml/kg/min) 51.4 ± 6.8 51.1 ± 7.0 51.9 ± 6.2
  
Figure 1. Time Trial Performance 
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Figure 2. Genotype and Time Trial Performance
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Figure 3. Time-of-Day and Time Trial Performance
James Madison University 
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James Madison University 
Department of Kinesiology 
Consent for Investigative Procedure 
 
I, ______________________, hereby agree on _____________ (date) to participate in the 
research project conducted by Christopher J. Womack, Ph.D., Nicholas D. Luden, 
Ph.D., Mike Saunders, Ph.D., Mark Pataky, and Jenna Goffe from James Madison 
University titled The Influence of a CYP1A2 Polymorphism on the Ergogenic Effects of 
a Caffeine Mouth rinse. 
The purpose of this study is to determine whether or not mouth rinsing with 
caffeine enhances high intensity cycling performance in individuals that do not 
benefit from caffeine intake due to their genetic predisposition. 
 
Subject Responsibility 
I understand that I will undergo the following testing in the study: 
This study consists of seven separate exercise tests performed on a stationary cycle 
(cardiovascular fitness test, two familiarization tests, and 4 3-km time trial tests). All 
testing will occur in Godwin Hall, room 209, on the campus of James Madison 
University.  You will also be asked about lifestyle behavior such as smoking and 
physical activity and complete dietary and physical activity records. The total time 
commitment is estimated to be less than four hours. 
 
Cardiovascular Fitness Test: 
 
If you meet the criteria for the study, the researchers will measure your height and 
body weight and you will then be asked to perform a cardiovascular fitness test on a 
bicycle ergometer to determine your peak oxygen consumption (VO2max). You will be 
asked to ride stationary bicycle ergometer at an initial workload that is ‘fairly easy’. 
The workload will be increased every two minutes during the test. You will be 
encouraged to continue to cycle until you request to stop due to fatigue or are 
unable to continue at a cadence of >50 revolutions per minute. To assess oxygen 
consumption throughout the test, you   will need to breathe through a 
mouthpiece/breathing apparatus that collects your expired breath throughout the 
test (10-15 minutes).   
 
Familiarization and Time Trial Sessions:  
 
During the familiarization and time trials, you will be asked to complete a 5-min 
warm up at a self selected intensity followed by 3-km time trial (TT) on a cycle 
ergometer that will last 3-5 minutes. Each time trial is to be approached with a 
competition mentality. Between test preparation and completion of the exercise 
test, each of these tests should take approximately 15-20 minutes.  
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Supplementation Protocol: 
 
No supplementation will be provided during the familiarization trials. However, you 
will be asked to practice with the mouth rinse prior to these trials. For the mouth 
rinse, Dixie cups filled with 25 ml of solution with or without caffeine will be 
provided 5 minutes, and 30 seconds prior to the TT. You will be instructed to swish 
the solution in your mouth for 10 seconds, upon which you will spit it into a bucket.  
The remaining four visits will be experimental trials whereby separate treatments 
will be provided. The treatments will be: 1. Caffeine mouth rinse; mouth rinse 
solution administered immediately prior to- and during exercise where you will be 
instructed to only rinse the caffeine solution in your mouth and then spit it out 
(without swallowing). A placebo pill will also be administered 1 hour prior to the 
trial. 2.  Caffeine pill; you will ingest the pill whole 1 hour prior to the TT. A placebo 
mouth rinse solution will also be administered. 3. Caffeine pill + caffeine mouth 
rinse; a caffeine pill and caffeine mouth rinse will be administered. 4. Placebo; a 
placebo pill and placebo mouth rinse will be administered.  
 
Dietary, Exercise, and Time of Day Controls: 
 
You will record food intake 24 hours prior to your first experimental trial. You will 
then be provided with a copy of your initial dietary log, which you will be asked to 
use to replicate your food intake for 24 hrs preceding each subsequent experimental 
trial. Additionally, you will abstain from any alcohol and caffeine for 24 hrs and 12 
hrs prior to the experimental trials, respectively. Finally, you will avoid food intake 
for 2 hours preceding each experimental trial.  
 
You will avoid heavy exercise for 48 hrs prior to each experimental trial, record all 
physical activity performed during this time frame, and maintain consistent exercise 
habits between trials  
 
All experimental trials will be separated by 3-7 days and performed at the same 
time of day, with all trials starting within a 2-hour range.   
 
 
 
DNA Sampling:  
 
We will extract a sample of your DNA from your blood sample.  The DNA will be 
stored in our laboratory freezer for up to 3 years, but the sample will be coded so 
that nobody except the primary investigators can detect which sample is yours. The 
DNA testing will involve determining sequences of DNA for specific genes that are 
related to caffeine metabolism. We will not use this DNA for any other purpose.  The 
results of this genetic testing will only be available to the primary investigator and 
you. These results will not be made public and will be stored in a locked file cabinet.   
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Potential Risks  
 
According to the American College of Sports Medicine’s Guidelines for Exercise 
Testing and Prescription, the risk associated with vigorous exercise in individuals 
categorized as “low risk” is very minimal, and physician supervision is not 
necessary.  The exercise testing conditions are likely safer than the typical exercise 
environments of the participants.  Subjects that do not meet ACSM criteria for “low 
risk” will not be allowed to participate in the study.  A physician will be available by 
pager if the need for medical attention arises throughout the study period.  In the 
unlikely event of cardiac or other complications during exercise, an emergency plan 
is in place. This includes immediate access to a phone to call emergency personnel. 
In addition, at least one of the listed investigators will be present during all 
laboratory testing sessions, and all are CPR certified.  
 
The risks of blood sampling using venipuncture include possible mild bruising, and 
the risk of transfer of blood-borne pathogens, as well as possible risks of infection or 
skin irritation.  These risks are considered to be minimal, and all safety precautions 
for handing blood samples will be followed according to Occupational Safety and 
Health Administration (OSHA) protocols, including: investigators will wear latex 
gloves at all times during blood sampling and testing. A sharps container lined with 
a biohazard bag will be used for all sharp objects involved in the blood sampling; all 
other materials (i.e. gloves, gauze pads, etc.) used during the sampling will be put in 
a separate waste disposal unit lined with a biohazard bag. All trash bags will be 
taken to Rockingham Memorial Hospital for disposal.  All investigators who will be 
involved in blood draws (and handling of blood) have been trained in these 
phlebotomy techniques, and completed JMU blood-borne pathogen training.   
 
If you have a wheat allergy you should not participate in this study. 
 
 
Potential Benefits  
 
There are no known direct benefits. However, volunteering for this project will help 
determine the impact of a caffeine mouth rinse on cycling performance. Performance 
Incentive – This monetary benefit will only apply to two males and two females. The 
top 5 female performers (fastest finishing time under the placebo conditions) will be 
entered into a drawing to win a single $150 WellsOne Prepaid Visa Card whereas 
performers 6-10 will be entered into a drawing to win a single $75 Card. An 
identical approach will be applied to male subjects (1 $150 Card and 1 $75 Card). 
 
Confidentiality  
The results of this research will be presented at conferences and published in 
exercise science journals.  The results of this project will be coded in such a way that 
your identity will not be attached to the final form of this study.  The researcher 
retains the right to use and publish non-identifiable data.  However, you can ask that 
your data be removed from the study at any point prior to presentation and 
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publication.  While individual responses are confidential, aggregate data will be 
presented representing averages or generalizations about the responses as a whole.  
All data will be stored in a secure location accessible only to the researcher.  Final 
aggregate results will be made available to you upon request. 
 
 
Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without 
consequences of any kind.  Your right to withdraw includes the right to request that 
your DNA and blood samples be discarded at any time.  You should be aware that 
the DNA sample is subject to court subpoena. 
 
Questions 
You may have questions or concerns during the time of your participation in this 
study, or after its completion.  If you have any questions about the study, contact 
Nicholas D. Luden, Ph.D. at ludennd@jmu.edu or by phone at 540-568-4068. 
 
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given 
satisfactory answers to my questions.  The investigator provided me with a copy of 
this form.  I certify that I am at least 18 years of age. 
 
   
Name of Participant  (Printed)  Name of Researcher(s)  (Printed) 
   
Name of Participant  (Signed)  Name of Researcher(s)  (Signed) 
   
  Date    Date 
 
For questions about your rights as a research subject, you may contact the chair of 
JMU’s Institutional Review Board (IRB).  Dr. David Cockley, (540) 568-2834, 
cocklede@jmu.edu.  
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James Madison University 
Department of Kinesiology 
Health Status Questionnaire 
  
Instructions: Complete each question accurately. All information provided is 
confidential.  
 
Part I:  General Information  
  
1. Sex: Male        Female 
 
2. Participant Number: 
  
3. Date of Birth  (Month/ Day/ Year) 
 
 
Part II: Medical History  
  
4. Circle any that died of heart attack before age 65:  Father  Mother  Brother  
Sister  Grandparent  
   
  
5. Date of last medical exam: _____________ Last physical fitness test: 
_______________  
  
6. Circle operations you have had:  Back   Heart   Kidney   Eyes    Joint    Neck     
Ears     Hernia     
                                        
        Lung     Other ________________  
  
7. Please circle any of the following for which you have been diagnosed or 
treated by a physician or health professional:  
  
Alcoholism     Diabetes      Kidney Problems  
Anemia (sickle cell)   Emphysema      Mental Illness  
Anemia (other)   Epilepsy      Muscular Injury  
Asthma      Eye Problems     Neck Strain  
Back Strain     Gout        Obesity  
Bleeding trait     Hearing Loss      Orthopedic Injuries  
Bronchitis, chronic    Heart Problem     Phlebitis  
Cancer       High Blood Pressure  Rheumatoid arthritis  
Cirrhosis, liver    Hypoglycemia     Stroke  
Concussion     Hyperglycemia    Thyroid problem  
Congenital defect   Infectious Mononucleosis Ulcer  
Other _____________________  
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8. Circle all medications taken in the last six months:  
 
Blood thinner    Epilepsy medication     Nitroglycerin  
Diabetic pill    Heart-rhythm medication    Other 
__________________  
Digitalis     High-blood pressure medication  
Diuretic     Insulin  
  
 
9. Any of these health symptoms that occur frequently is the basis for medical 
attention. Circle the  number indicating how often you have each of the following:  
  
5 = Very often    4 = Fairly often   3 = Sometimes   2 = Infrequently   1= 
Practically never  
  
a. cough up blood     f. chest pain  
    1   2   3   4   5                   1   2   3   4   5  
  
b. abdominal pain     g. swollen joints  
    1   2   3   4   5                     1   2   3   4   5  
  
c. low back pain     h. feel faint  
    1   2   3   4   5                    1   2   3   4   5  
  
d. leg pain       i. dizziness  
    1   2   3   4   5                   1   2   3   4   5  
  
e. arm or shoulder pain   j. breathless on slight exertion  
    1   2   3   4   5                   1   2   3   4   5  
  
 
Part III: Health Related Behavior  
  
10. Do you smoke?  Yes      No  
  
11. If you are a smoker, indicate the number of smoked per day:  
  
Cigarettes: 
 
 40 or more   20-39   10-19   1-9  
  
Cigars or pipes only:   
 
 5 or more or any inhaled  less than 5, none inhaled  
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12. Do you exercise regularly? Yes No  
  
 
 
13. How many times in a week do you spend at least 30 minutes in moderate to 
strenuous/vigorous exercise?  
  
 1  2  3  4  5  6  7  days per week  
 
 
Average Exercise Habits over the Past 2 Months: 
Avg. # days of exercise per week    
Avg. # of days of aerobic exercise per week    
Avg. # of days of cycling per week    
 
  
 
14. Can you walk 4 miles briskly without fatigue? Yes No  
  
15. Can you jog 3 miles continuously at a moderate pace without discomfort?  
Yes      No  
  
16. Weight now: __________ lb.  One year ago: __________ lb   Age 21: 
__________ lb  
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Caffeine Habits Questionnaire 
 
Please list your approximate WEEKLY intake of the following 
 
Cups of coffee: 
 
Cups of tea: 
 
Cans (12oz) of caffeinated soda: 
 
Servings of chocolate: 
 
Doses of caffeinated pills (No-Doz, Vivarin, etc.): 
 
Other caffeinated beverages not listed (please list specific drink and weekly intake): 
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INSTRUCTIONS FOR KEEPING YOUR 24-HOUR  FOOD RECORD 
 
Keep your record for three days per trial. You will include the day before, the day of, 
and the day after each trial.  Include all meals, snacks, nibbling, and beverages 
including water and cocktails 
 
1. Fill out the date and day of the week at the top of food record sheet 
 
2. Record the time you consumed your food and/or drink.  To be most accurate, 
fill out the food record as soon as you finish eating. 
 
3. List the first food and/or drink you consumed when you began your day and 
continue to record until you consume your last food and/or drink of your day 
(usually before bedtime) 
 
4. List each food and/or drink on a separate line 
 Example:  cereal with milk, cereal and milk should each be on separate lines 
                 spaghetti, noodles and sauce should each be on separate lines 
 
 Combination foods:   
  List parts of food on separate lines 
  Include preparation method, quantity, and brand name of each food 
 Example:  Sandwich (4 oz healthy choice turkey, 2 slices Sara Lee  
  wheat bread, 1 tbsp Hellman’s light mayo, 2 oz Kraft American 
  cheese, 1 slice of red fresh tomato) 
   
5. Record the method of preparation 
  Example:  fried, baked, grilled 
                             salt, oil (olive, canola, corn, other) butter or margarine, spices, etc. 
 
6. Record quantity consumed 
  Do not record any food not eaten 
  Example:  two cups of vegetables but ate half, so record one cup 
   
  Quantity of food and/or drink 
  Example:  cups, ounces, liters, grams, each, or other unit of measure 
  Example:  1 cup of vegetables, 4 ounces of meat, one medium apple 
 
7. Record brand name 
  Example:  fast food chain name and/or package name 
  Example:  Wendy’s, Betty Crocker, Lean Cuisine, Gatorade 
 
8. Place any helpful food labels in manila envelope that is attached to folder 
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USE THE FOLLOWING TO HELP DETERMINE PORTION SIZES AND TYPES OF FOODS 
                                      PLEASE SPECIFY 
Beverages 
Sugar or creamer? 
Regular or sugar-free? 
Alcohol content? 
Name of drink and ingredients (if mixed drink) 
Breads 
Butter or margarine added? 
Cereal/Milk 
Milk, sugar, or fruit added? 
The type of milk? (skim, 1%, 2%, whole) 
Cereal:  dry or cooked measure? 
Dairy 
Is yogurt fruited or plain? 
% fat of milk or yogurt? 
Indicate brand name of cheese substitute and/or     nondairy creamer. 
Desserts 
Whipped topping added? 
Frosting? 
Fat modified (i.e., reduced)? 
Sugar-free? 
Eggs 
Preparation method (scrambled, hard-boiled, etc)? 
Fat used in cooking? 
Fast Food 
What restaurant? 
If not a national fast food chain, describe food in detail 
Size order of fries?  Super-size? 
ExtRa toppings on sandwich? 
Fats/Oils 
Regular or salt-free? 
Stick, tub, or liquid margarine? 
Reduced calorie or diet product? 
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Fish 
Water or oil packed (fresh or canned)? 
Baked or fried (With batter or without)? 
Type of fat added? 
Raw or cooked weight? 
Fruit 
Sweetened or unsweetened? 
Fresh, canned, or frozen? 
With or without skin? 
Meats 
Visible fat removed? 
Light or dark meat?  Raw or cooked? 
Sugars and Sweets 
Regular or reduced-calorie? 
Don’t forget hard candy as well as chocolate. 
Vegetables 
Raw or cooked? 
Fresh, frozen, or canned? 
Low-sodium or regular? 
Added fat or sauce? 
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Helpful Hints with Portion Sizes 
 
• 1 teaspoon (5 ml)  
o about the size of the top half / tip of your thumb  
• 1oz (28g) 
o approximately inch cube of cheese  
o volume of four stacked dice  
o slice of cheese is about the size of a 3 1/2 inch computer disk  
o chunk of cheese is about as thick as 2 dominoes  
o 1 handful (palm) of nuts  
• 2 ounces (57 g)  
o 1 small chicken leg or thigh  
o 1/2 cup of cottage cheese or tuna  
• 3 ounces (85 g)  
o serving of meat is about the size of a deck of playing cards (3 exchanges)  
o the size of the palm of your hand 
o 1/2 of whole chicken breast  
o 1 medium pork chop  
o 1 small hamburger  
o unbreaded fish fillet  
• 1/2 cup (118 ml)  
o fruit or vegetables can fit in the palm of your hand  
o about the volume of a tennis ball  
• 1 cup (236 ml)  
o about the size of a woman's fist  
o breakfast cereal goes halfway up the side of a standard cereal bowl  
o broccoli is about the size of a light bulb  
• 1 medium apple = A tennis ball  
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Appendix V 
 
24-HOUR DIET RECORD 
Subject number____________  Date______________   Day of Week______________ 
 
 
Time Food and/or Drink Method of Preparation Quantity Consumed Brand Name 
    
    
    
    
    
    
    
    
    
    
 
Adapted From:  Lee RD, Nieman DC. Nutritional Assessment. 2nd ed. United States of America: Mosby; 1996
   
 
Daily Activity Records 
Subject #    Trial #    Date:   
 
Date Type of Exercise Performed 
Duration of Exercise 
(minutes) 
Intensity of Exercise 
(use scale below) 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
    
 
 
Intensity Scale 
 
6 
7 Very, very light 
8 
9 Very light 
10 
11 Fairly light 
12 
13 Somewhat hard 
14 
15 Hard 
16 
17 Very hard 
18 
19 Very, very hard 
20 
 
Appendix VI 
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Treatment Recall 
 
Subject Number: ______________ 
 
Date: _______________ 
 
 
 
       Trial 1             Trial 2                       Trial 3       Trial 4 
 
Capsule:         PLA       CAF        PLA      CAF      PLA       CAF         PLA     CAF 
 
Confidence:    ___________        ___________             ___________         ___________ 
 
 
 
                             Trial 1             Trial 2                        Trial 3       Trial 4 
 
Rinse:             PLA       CAF        PLA      CAF      PLA       CAF         PLA     CAF 
 
Confidence:    ___________        ___________             ___________         ___________ 
 
 
 
 
 
**Confidence rated on a scale from 1-10. 10 being 100% confident and 1 being not 
confident at all.  
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